Benefits can include: Lower blood pressure Lower total cholesterol Better liver health for those with metabolic dysfunctionassociated steatotic liver disease (MASLD) Lower blood sugar and reduced diabetes risk Lower risk of kidney disease Tirzepatide and orforglipron are newer drugs that dont yet have results from long-term cardiovascular health trials
Diet, activity and behavioral change remain cornerstones of care
GLP-1 agonists were initially approved for treating type 2 diabetes, with subsequent approvals for chronic weight management and reduction of the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 diabetes
Exercise supports GLP-1 production independently Physical activity, particularly moderate-intensity aerobic exercise, has been shown to independently increase Akkermansia muciniphila populations and improve GLP-1 sensitivity
Our friendly staff will assist you in setting up a consultation tailored to your needs
While mild hypercapnia alone is unlikely to trigger amyloid formation, the cumulative interplay of chronic disease, inflammation, impaired clearance pathways, and aging-associated acidification may lower the threshold at which misfolding and aggregation become pathophysiologically relevant